December 9, 2020 -- Thermo Fisher Scientific is expanding its footprint in North America and Europe in sterile drug product development and commercial manufacturing.
The company is expanding sites in Greenville, NC, Swindon, U.K., and Ferentino and Monza, Italy. The investments will add 15 development and current good manufacturing practice commercial production lines. The additions will support a range of capabilities in live virus, aseptic liquid handling, and lyophilized vial filling. Cumulatively, the projects will create approximately 1,000 new jobs and be completed over the next two years.
In other news, the company is also adding a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.